Oculis Holding AG

Oculis Holding AG is a global biopharmaceutical company dedicated to saving sight and improving eye care through breakthrough innovations. Headquartered in Zug, Switzerland, the company also maintains operations in the U.S., Iceland, France, and Hong Kong.

The company's late-stage clinical pipeline focuses on addressing significant unmet medical needs in ophthalmology and neuro-ophthalmology. Key product candidates include OCS-01, a topical retinal candidate for diabetic macular edema (DME); Licaminlimab (formerly OCS-02), a topical biologic candidate for dry eye disease (DED); and Privosegtor (formerly OCS-05), a disease-modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy. Oculis leverages its proprietary OPTIREACH® solubilizing formulation technology to develop these treatments.

Oculis is a publicly traded company, having gone public on March 3, 2023, through a SPAC merger with European Biotech Acquisition Corp. Recent developments include the completion of the last patient visit in the Phase 3 DIAMOND program for OCS-01 eye drops for DME, with topline results anticipated in June 2026 and a potential New Drug Application (NDA) submission in Q4 2026. Additionally, Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Priority Medicines (PRIME) designation from the European Medicines Agency for optic neuritis. The company is led by CEO Riad Sherif, with recent executive appointments including Snehal Shah as President of R&D and Katie Kazem as Chief Legal Officer.